A Phase 3 Open-Label Randomized Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma

Brief description of study

The purpose of this study involves research and is being conducted to determine the safety and efficacy of the investigational agent, rAd-IFN, when given with Celecoxib and Gemcitabine. The sponsor believes that rAd-IFN in combination with Celecoxib and Gemcitabine may help inhibit your tumor growth.

Clinical Study Identifier: s17-01785
ClinicalTrials.gov Identifier: NCT03710876
Principal Investigator: Daniel H. Sterman
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.